Nanobodies’ duo facilitates ultrasensitive serum HER-2/neu immunoassays via enhanced avidity interactions
Analytica Chimica Acta · 2025
DOI: 10.1016/j.aca.2024.343472 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytica Chimica Acta, 2025. Verfasst von Suchanat Boonkaew und 4 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Nanoscience Center (iNANO), Faculty of Natural Sciences, Aarhus University, Gustav Wieds Vej 14, 8000, Aarhus C, Denmark. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Single-Domain Antibodies. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk Foundation, Danmarks Grundforskningsfond.
Abstract (Originalsprache)
BACKGROUND: Existing liquid biopsy assays for protein biomarkers of cancer are mostly based on antibodies (Ab) contributing unfavorably to their high cost. Easy to express and modify in vitro, nanobodies may be a cost-effective alternative to Ab. RESULTS: We show that serum HER-2/neu, a biomarker and target of aggressive HER-2/neu(+) cancers, can be accurately detected in a 1.2 h electrochemical cellulase-linked sandwich nanobody/aptamer assay on magnetic beads. Using a single nanobody receptor, 2Rs15d or 2Rb17c, reduces immunoassay's sensitivity by 35%-26 %. A combination of two nanobodies as a duo-receptor recovers the sensitivity of the enzyme-linked nanobody/aptamer-sorbent assay (ELNASA) to 11.9 ± 2.8 μC fM-1, due to the avidity effects making the nanobodies-duo binding properties comparable to those of Ab. Down to 0.1 fM HER-2/neu was detected by ELNASA in serum samples, with no interference from other blood-circulating proteins. In a 30 healthy-volunteers trial, ELNASA more accurately than optical ELISA assayed serum HER-2/neu. SIGNIFICANCE: ELNASA performance rivals that of ELISA, yet estimated to be at least 200 times cheaper, due to the lower cost of nanobodies production, and may be better suited for routine clinical analysis of HER-2/neu, particularly, in low- and middle-income settings with limited resources. The ELNASA approach is generic and may be adapted for specific and ultrasensitive analysis of other blood-circulating proteins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interdisciplinary Nanoscience Center (iNANO), Faculty of Natural Sciences, Aarhus University, Gustav Wieds Vej 14, 8000, Aarhus C, Denmark.
- Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200, Aarhus N, Denmark; Department of Biomedicine, Aarhus University, Høegh-Guldbergs Gade 10, 8000, Aarhus C…
- Interdisciplinary Nanoscience Center (iNANO), Faculty of Natural Sciences, Aarhus University, Gustav Wieds Vej 14, 8000, Aarhus C, Denmark; Department of Molecular Biology and Genetics, Aarhus University, Universitetsby…
- Interdisciplinary Nanoscience Center (iNANO), Faculty of Natural Sciences, Aarhus University, Gustav Wieds Vej 14, 8000, Aarhus C, Denmark. Electronic address: elena.ferapontova@inano.au.dk.
Förderung
- Novo Nordisk Foundation
- Danmarks Grundforskningsfond
Zitieren
APA
Boonkaew, S., Teodori, L., Vendelbo, M. H., Kjems, J., & Ferapontova, E. E. (2025). Nanobodies’ duo facilitates ultrasensitive serum HER-2/neu immunoassays via enhanced avidity interactions. Analytica Chimica Acta. https://doi.org/10.1016/j.aca.2024.343472
Vancouver
Boonkaew S, Teodori L, Vendelbo MH, Kjems J, Ferapontova EE. Nanobodies’ duo facilitates ultrasensitive serum HER-2/neu immunoassays via enhanced avidity interactions. Analytica Chimica Acta. 2025. doi:10.1016/j.aca.2024.343472
BibTeX
@article{Boonkaew2025,
author = {Boonkaew, Suchanat and Teodori, Laura and Vendelbo, Mikkel H and Kjems, Jørgen and Ferapontova, Elena E},
title = {Nanobodies’ duo facilitates ultrasensitive serum HER-2/neu immunoassays via enhanced avidity interactions},
journal = {Analytica Chimica Acta},
year = {2025},
doi = {10.1016/j.aca.2024.343472}
}
EUVIMED